Novo Nordisk A/S (NOVO-B.CO)

DKK 399.95

(-2.48%)

Operating Income Summary of Novo Nordisk A/S

  • Novo Nordisk A/S's latest annual operating income in 2023 was 102.57 Billion DKK , up 37.11% from previous year.
  • Novo Nordisk A/S's latest quarterly operating income in 2024 Q2 was 25.52 Billion DKK , down -21.24% from previous quarter.
  • Novo Nordisk A/S reported an annual operating income of 74.8 Billion DKK in 2022, up 27.56% from previous year.
  • Novo Nordisk A/S reported an annual operating income of 58.64 Billion DKK in 2021, up 8.35% from previous year.
  • Novo Nordisk A/S reported a quarterly operating income of 32.41 Billion DKK for 2024 Q1, up 21.1% from previous quarter.
  • Novo Nordisk A/S reported a quarterly operating income of 23.88 Billion DKK for 2023 Q2, down -4.47% from previous quarter.

Annual Operating Income Chart of Novo Nordisk A/S (2023 - 1989)

Historical Annual Operating Income of Novo Nordisk A/S (2023 - 1989)

Year Operating Income Operating Income Growth
2023 102.57 Billion DKK 37.11%
2022 74.8 Billion DKK 27.56%
2021 58.64 Billion DKK 8.35%
2020 54.12 Billion DKK 3.13%
2019 52.48 Billion DKK 11.08%
2018 47.24 Billion DKK -3.51%
2017 48.96 Billion DKK 1.1%
2016 48.43 Billion DKK -2.05%
2015 49.44 Billion DKK 43.35%
2014 34.49 Billion DKK 9.52%
2013 31.49 Billion DKK 6.85%
2012 29.47 Billion DKK 31.73%
2011 22.37 Billion DKK 18.44%
2010 18.89 Billion DKK 26.51%
2009 14.93 Billion DKK 20.38%
2008 12.4 Billion DKK 38.53%
2007 8.95 Billion DKK -1.81%
2006 9.12 Billion DKK 12.94%
2005 8.07 Billion DKK 14.87%
2004 7.02 Billion DKK 60.45%
2003 4.38 Billion DKK -7.19%
2002 4.72 Billion DKK -15.66%
2001 5.59 Billion DKK 31.91%
2000 4.24 Billion DKK 17.37%
1999 3.61 Billion DKK 479.8%
1998 623.52 Million DKK -46.5%
1997 1.16 Billion DKK 7.32%
1996 1.08 Billion DKK -26.28%
1995 1.47 Billion DKK 7.86%
1994 1.36 Billion DKK -6.77%
1993 1.46 Billion DKK 1135.76%
1992 118.55 Million DKK -87.53%
1991 950.89 Million DKK 43.03%
1990 664.81 Million DKK -16.22%
1989 793.56 Million DKK 14.64%

Peer Operating Income Comparison of Novo Nordisk A/S

Name Operating Income Operating Income Difference
ALK-Abelló A/S 666 Million DKK -15301.502%
Bavarian Nordic A/S 1.49 Billion DKK -6749.578%
Genmab A/S 5.32 Billion DKK -1827.72%
Gubra A/S -49.41 Million DKK 207668.246%
Orphazyme A/S -27.04 Thousand DKK 379327787.586%
Pharma Equity Group A/S -25.29 Million DKK 405643.036%
Zealand Pharma A/S -572.23 Million DKK 18025.059%